| Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab HT Lee, JY Lee, H Lim, SH Lee, YJ Moon, HJ Pyo, SE Ryu, W Shin, ... Scientific reports 7 (1), 5532, 2017 | 216 | 2017 |
| Visible-light-triggered prodrug nanoparticles combine chemotherapy and photodynamic therapy to potentiate checkpoint blockade cancer immunotherapy J Choi, MK Shim, S Yang, HS Hwang, H Cho, J Kim, WS Yun, Y Moon, ... ACS nano 15 (7), 12086-12098, 2021 | 100 | 2021 |
| Cancer-activated doxorubicin prodrug nanoparticles induce preferential immune response with minimal doxorubicin-related toxicity S Yang, MK Shim, WJ Kim, J Choi, GH Nam, J Kim, J Kim, Y Moon, ... Biomaterials 272, 120791, 2021 | 90 | 2021 |
| Cancer-specific drug-drug nanoparticles of pro-apoptotic and cathepsin B-cleavable peptide-conjugated doxorubicin for drug-resistant cancer therapy MK Shim, Y Moon, S Yang, J Kim, H Cho, S Lim, HY Yoon, JK Seong, ... Biomaterials 261, 120347, 2020 | 75 | 2020 |
| In situ one-step fluorescence labeling strategy of exosomes via bioorthogonal click chemistry for real-time exosome tracking in vitro and in vivo S Song, MK Shim, S Lim, Y Moon, S Yang, J Kim, Y Hong, HY Yoon, ... Bioconjugate chemistry 31 (5), 1562-1574, 2020 | 64 | 2020 |
| Anti-PD-L1 peptide-conjugated prodrug nanoparticles for targeted cancer immunotherapy combining PD-L1 blockade with immunogenic cell death Y Moon, MK Shim, J Choi, S Yang, J Kim, WS Yun, H Cho, JY Park, Y Kim, ... Theranostics 12 (5), 1999, 2022 | 56 | 2022 |
| Combination of cancer-specific prodrug nanoparticle with Bcl-2 inhibitor to overcome acquired drug resistance J Kim, MK Shim, S Yang, Y Moon, S Song, J Choi, J Kim, K Kim Journal of controlled release 330, 920-932, 2021 | 45 | 2021 |
| Doxorubicin-loaded PLGA nanoparticles for cancer therapy: molecular weight effect of PLGA in doxorubicin release for controlling immunogenic cell death Y Choi, HY Yoon, J Kim, S Yang, J Lee, JW Choi, Y Moon, J Kim, S Lim, ... Pharmaceutics 12 (12), 1165, 2020 | 43 | 2020 |
| The safe and effective intraperitoneal chemotherapy with cathepsin B-specific doxorubicin prodrug nanoparticles in ovarian cancer with peritoneal carcinomatosis J Kim, MK Shim, YJ Cho, S Jeon, Y Moon, J Choi, J Kim, J Lee, JW Lee, ... Biomaterials 279, 121189, 2021 | 31 | 2021 |
| Sustained and long-term release of doxorubicin from PLGA nanoparticles for eliciting anti-tumor immune responses J Kim, Y Choi, S Yang, J Lee, J Choi, Y Moon, J Kim, N Shim, H Cho, ... Pharmaceutics 14 (3), 474, 2022 | 21 | 2022 |
| Cathepsin B-overexpressed tumor cell activatable albumin-binding doxorubicin prodrug for cancer-targeted therapy H Cho, MK Shim, S Yang, S Song, Y Moon, J Kim, Y Byun, CH Ahn, K Kim Pharmaceutics 14 (1), 83, 2021 | 15 | 2021 |
| All-in-one glycol chitosan nanoparticles for co-delivery of doxorubicin and anti-PD-L1 peptide in cancer immunotherapy S Song, MK Shim, S Yang, J Lee, WS Yun, H Cho, Y Moon, JY Min, ... Bioactive Materials 28, 358-375, 2023 | 14 | 2023 |
| Implantable micro-scale LED device guided photodynamic therapy to potentiate antitumor immunity with mild visible light J Choi, IS Lee, JS Lee, S Jeon, WS Yun, S Yang, Y Moon, J Kim, J Kim, ... Biomaterials Research 26 (1), 56, 2022 | 9 | 2022 |
| Cancer-specific delivery of proteolysis-targeting chimeras (PROTACs) and their application to cancer immunotherapy Y Moon, SI Jeon, MK Shim, K Kim Pharmaceutics 15 (2), 411, 2023 | 8 | 2023 |
| Tumor-specific monomethyl auristatin E (MMAE) prodrug nanoparticles for safe and effective chemotherapy H Cho, MK Shim, Y Moon, S Song, J Kim, J Choi, J Kim, Y Lee, JY Park, ... Pharmaceutics 14 (10), 2131, 2022 | 7 | 2022 |
| Preclinical development of carrier-free prodrug nanoparticles for enhanced antitumor therapeutic potential with less toxicity MK Shim, S Yang, J Park, JS Yoon, J Kim, Y Moon, N Shim, M Jo, Y Choi, ... Journal of Nanobiotechnology 20 (1), 436, 2022 | 7 | 2022 |
| Cancer cell-specific and pro-apoptotic SMAC peptide-doxorubicin conjugated prodrug encapsulated aposomes for synergistic cancer immunotherapy J Kim, MK Shim, Y Moon, J Kim, H Cho, WS Yun, N Shim, JK Seong, ... Journal of Nanobiotechnology 22 (1), 109, 2024 | | 2024 |
| Photo-induced crosslinked and anti-PD-L1 peptide incorporated liposomes to promote PD-L1 multivalent binding for effective immune checkpoint blockade therapy Y Lee, S Song, S Yang, J Kim, Y Moon, N Shim, HY Yoon, S Kim, ... Acta Pharmaceutica Sinica B 14 (3), 1428-1440, 2024 | | 2024 |
| Accurately controlled tumor temperature with silica-coated gold nanorods for optimal immune checkpoint blockade therapy WS Yun, W Yang, MK Shim, S Song, J Choi, J Kim, J Kim, Y Moon, SH Jo, ... Biomaterials Research, 0 | | |
